Adeno-associated virus vectors encoding modified g6pc and uses thereof

A carrier and encoding technology, applied in the direction of viruses/phages, medical preparations containing active ingredients, and the use of vectors to introduce foreign genetic materials, etc.

Active Publication Date: 2018-01-26
UNITED STATES OF AMERICA
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although previous gene therapy studies using recombinant adeno-associated viruses (AAV) carrying G6Pase-α have been performed in animal models of GSD-Ia, none were able to completely correct hepatic G6Pase-α deficiency

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adeno-associated virus vectors encoding modified g6pc and uses thereof
  • Adeno-associated virus vectors encoding modified g6pc and uses thereof
  • Adeno-associated virus vectors encoding modified g6pc and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0164] Example 1: Construction and characterization of human G6PC (G6Pase-α) mutants for AAV-mediated gene therapy

[0165] This example describes the generation of 18 human G6PC mutants and the identification of specific G6Pase-α mutants with increased phosphohydrolase activity.

[0166] Construction of G6PC mutant

[0167] To construct the human G6PC mutant, the pSVL vector containing nucleotides 1 to 1074 of human G6PC cDNA (the entire coding region, where the start codon ATG is at nucleotides 1-3; SEQ ID NO: 11) was used as a template . For PCR-directed mutagenesis, two external PCR primers are used to amplify the template. The external primers match nucleotides 1 to 20 (sense) and 1055 to 1074 (antisense), located in a 20-nucleotide long sense and The outer side of the antisense mutant primer (flanked), where the codon to be mutated is in the middle of the mutant primer (see Figure 4 And Table 1) below. The template of the hG6PC-S298C / A301V double mutant is the pSVL-hG6PC-S2...

Embodiment 2

[0189] Example 2: Evaluation of the minimum carrier dose required to correct liver G6Pase-α deficiency

[0190] This example describes a study to determine the minimum dose required to restore G6Pase-α activity to a level that prevents the development of HCA / HCC and maintains glucose homeostasis.

[0191] GSD-Ia is characterized by impaired glucose homeostasis and long-term complications hepatocellular adenoma (HCA) (Chou et al., Nat Rev Endocrinol 6:676-688, 2010). The inventors have previously demonstrated that G6pc- / - mice treated with rAAV8-G6PC express ≥3% of normal liver G6Pase-α activity (which is equivalent to ≥5 units of G6Pase-α activity; 1 nmol / min / mg It is defined as a unit of G6Pase-α activity), which maintains glucose homeostasis to P70-P90 weeks of age and does not develop HCA (Lee et al., Hepatology 56: 1719-1729, 2012; PCT Publication No. WO 2015 / 081101, It is incorporated herein by reference).

[0192] This study was performed using purified rAAV8 vector (supplied...

Embodiment 3

[0200] Example 3: Treatment of human GSD-Ia using AAV-based gene therapy

[0201] This example describes an exemplary method of clinically using AAV vectors encoding modified G6PC to treat GSD-Ia.

[0202] Select patients diagnosed with GSD-Ia for treatment. Usually the patient is at least 18 years old and may or may not be pre-exposed to immunomodulation. The patient is administered a therapeutically effective amount of a recombinant AAV expressing modified G6PC, such as rAAV comprising SEQ ID NO: 4 or SEQ ID NO: 5, as described herein. Recombinant AAV can be administered intravenously. The appropriate therapeutic dose can be selected by the physician. In some cases, the therapeutically effective dose is 1×10 10 To 1×10 14 Virus particles (vp) / kg, such as about 1×10 11 Or 1×10 12 vp / kg. In most cases, a single dose is administered to the patient. In the absence of immune regulation, patients may only tolerate a single infusion of rAAV. If the subject is previously exposed to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Modified G6PC (glucose-6-phosphatase, catalytic subunit) nucleic acids and glucose-6-phosphatase-alpha (G6Pase-alpha) enzymes with increased phosphohydrolase activity are described. Also described arevectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing modified G6Pase-alpha. The disclosed AAV vectors and rAAV can be used for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type la (GSD-Ia), and complications thereof.

Description

[0001] Cross references to related applications [0002] This application claims the benefits of U.S. Provisional Application No. 62 / 096,400 filed on December 23, 2014, which is incorporated herein by reference in its entirety. Technical field [0003] The present disclosure relates to gene therapy vectors encoding modified glucose-6-phosphatase-α (G6PC) enzymes with enhanced activity and uses thereof, such as for the treatment of glycogen storage diseases (GSD) and complications related to GSD disease. Background of the invention [0004] Type Ia glycogen storage disease (GSD-Ia or von Gierke disease, MIM232200) is caused by a defect in glucose-6-phosphatase-α (G6Pase-α or G6PC), glucose- 6-phosphatase-α is an enzyme mainly expressed in the liver, kidney and intestine (Chou et al., Nat Rev Endocrinol 6:676-688, 2010). G6Pase-α is encoded by the G6PC gene and is a hydrophobic protein anchored in the endoplasmic reticulum (ER) through nine transmembrane helices (Chou et al., Nat Re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/55C12N9/16C12N15/864C12N7/01A61K38/46A61P3/08A61P35/00A61P13/12
CPCA61K38/00C12N9/16C12Y301/03009A61K38/47C12Y302/00A61P1/16A61P13/12A61P3/00A61P35/00A61P3/08C12N15/85C12N15/8645A61K48/00A61K45/06C12N15/66
Inventor J·J·周
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap